Trial Profile
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Dexmethylphenidate/serdexmethylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Registrational
- Sponsors Zevra Therapeutics
- 26 Jun 2023 Results presented in the Corium Media Release.
- 26 Jun 2023 According to a Corium media release, results of a yearlong open-label safety study were published in the peer-reviewed journal Frontiers in Psychiatry.
- 22 May 2023 According to a Corium media release, a new analysis from this study published in the Journal of Child and Adolescent Psychopharmacology.